Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
Status:
Completed
Trial end date:
2019-08-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of dapagliflozin, a FDA approved diabetes
medication, on measures of nervous system function of the heart in patients with type 2
diabetes. The investigators will compare the effect of dapagliflozin with an active
comparator, glimepiride (a different FDA approved diabetes medication) on measures of heart
rate variability and assess whether dapagliflozin has modulating effects on measures of
nervous system function of the heart. This is a crossover study design where all participants
will receive both study medications equally (12-week intervention periods) in a certain
order.